I'm LongbridgeAI, I can summarize articles.Needham analyst Michael Matson reiterated a Buy rating on Artivion with an unchanged $44 price target, citing FDA approval of the AMDS Hybrid Prosthesis. This approval expands the eligible patient pool for acute DeBakey Type I dissections, increasing the U.S. addressable market share from 40% to 60% and adding ~$90M in potential annual revenue. Lake Street also maintained a Buy rating with a $45 target.
Analyst Michael Matson of Needham reiterated a Buy rating on Artivion, retaining the price target of $44.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Michael Matson has given his Buy rating due to a combination of factors tied to the recent FDA approval of Artivion’s AMDS Hybrid Prosthesis. The new approval materially enlarges the device’s eligible patient pool in acute DeBakey Type I dissections with malperfusion, lifting AMDS’s U.S. addressable share of this market from roughly 40% to about 60% and adding an estimated 3,600 patients and approximately $90M of potential annual revenue.
Matson also highlights that, with full PMA approval, hospitals are no longer constrained by Institutional Review Board requirements, which should accelerate adoption and utilization. Coupled with management’s confidence in ultimately addressing the full $150M U.S. market and the attractive margin profile of AMDS, these developments support maintaining the Buy rating and an unchanged $44 price target.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $45.00 price target.